Clinical Trial Update: High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating high-dose spironolactone (Aldactone) for diuretic-resistant heart failure has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Aldactone (spironolactone)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Heart Failure | Phase 4 | Status: WITHDRAWN